December 13, 2021

Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

Junshi Biosciences and Coherus to meet with US FDA to discuss 1L NSCLC BLA supplement submission SHANGHAI, China and REDWOOD CITY, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced positive results

Read More

Malaysia to open new Defence Attaché office in Egypt

KUALA LUMPUR, Dec 13 — The government plans to set up a new Defence Attaché Office in Egypt to support the Defence White Paper which emphasises efforts towards defence diplomacy, both at bilateral and multilateral levels.Deputy Defence Minister Datuk …

Read More

Copyright Amendment Bill tabled for first reading

KUALA LUMPUR, Dec 13 — A fine of up to RM200,000 or imprisonment not exceeding 20 years for those who commit offences relating to streaming technology is among the new subsections in the Copyright (Amendment) Bill 2021, which was tabled for the first …

Read More